Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, November 1998, p. 2893-2897, Vol. 42, No. 11
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Display of Functional
-Lactamase Inhibitory
Protein on the Surface of M13 Bacteriophage
Wanzhi
Huang,1
Joseph
Petrosino,1 and
Timothy
Palzkill1,2,*
Department of Microbiology and
Immunology1 and
Department of
Biochemistry,2 Baylor College of Medicine,
Houston, Texas 77030
Received 3 April 1998/Returned for modification 23 July
1998/Accepted 10 August 1998
 |
ABSTRACT |
The display of proteins on the surface of filamentous phage has
been shown to be a powerful method to select variants of a protein with
altered binding properties from large combinatorial libraries of
mutants. The
-lactamase inhibitory protein (BLIP) is a
165-amino-acid protein that binds and inhibits TEM-1
-lactamase-catalyzed hydrolysis of the penicillin and cephalosporin
antibiotics. Here we describe the construction of a new phagemid vector
and the use of this vector to display BLIP on the surface of
filamentous phage. It is shown that BLIP-displaying phage bind to
immobilized
-lactamase and that the binding can be competed off by
the addition of soluble
-lactamase. In addition, a two-step phage
enzyme-linked immunosorbent assay procedure was used to demonstrate
that the BLIP-displaying phage bind
-lactamase with a 50%
inhibitory concentration of 1 nM, which compares favorably with a
previously published Ki of 0.6 nM. A system has
therefore been established for protein engineering of BLIP to expand
its range of binding to other
-lactamases and penicillin-binding proteins.
 |
INTRODUCTION |
-Lactam antibiotics, such as the
penicillins and cephalosporins, are among the most often used
antimicrobial agents. Because of their widespread use, bacterial
resistance to these antibiotics has become an increasing problem
(7). The most common mechanism of resistance is the
production of
-lactamases.
-Lactamases are secreted to the
periplasm of gram-negative bacteria, or extracellularly in
gram-positive bacteria, where they hydrolyze
-lactam antibiotics to
create ineffective antimicrobials. There are a large number of
-lactamases which are found to be encoded either on plasmids or on
the bacterial chromosome (3). In gram-negative bacteria, the
most common plasmid-mediated
-lactamase is the TEM-1
-lactamase (30). This enzyme efficiently hydrolyzes penicillins and
many cephalosporins and is therefore a widespread source of
-lactam resistance (18).
An effective means of combating TEM-1
-lactamase-mediated resistance
has been the clinical use of small-molecule
-lactamase inhibitors
such as sulbactam and clavulanic acid (21). These molecules
do not possess significant antimicrobial activity themselves but are
used in conjunction with other
-lactam antibiotics, such as
ampicillin. The inhibitor protects the antibiotic from the action of
-lactamase and thereby restores the therapeutic value of the
antibiotic. However, in recent years, there have been many reports of
resistance to
-lactam-
-lactamase inhibitor combinations (12). This resistance is due to mutations in
-lactamase
that enable the enzyme to avoid inactivation by the inhibitor while retaining the ability to hydrolyze
-lactam antibiotics
(15).
The small-molecule inhibitor clavulanic acid is a natural product from
Streptomyces clavuligerus (19). In addition to
clavulanic acid, S. clavuligerus also produces a protein
inhibitor of
-lactamase, called
-lactamase inhibitory protein
(BLIP) (8). BLIP is a 165-amino-acid protein encoded by the
bli gene that binds and inhibits TEM-1
-lactamase, with a
reported Ki of 0.6 nM (28). BLIP also
binds to other
-lactamases from both gram-negative and gram-positive
bacteria, albeit with reduced affinity. In addition, BLIP has been
reported to inhibit the Enterococcus faecalis PBP 5 with a
Ki of 12 µM (28). The X-ray
structure of BLIP has been solved both alone and in complex with TEM-1
-lactamase and has revealed the residues making up the binding
surface of BLIP (27, 28). Using this information, it may be
possible to use site-directed mutagenesis techniques as a means of
increasing BLIP binding and inhibition of
-lactamases and
penicillin-binding proteins. If BLIP can be exploited as a molecular
scaffolding to engineer binding interactions, it may be possible to
create new BLIP-based antibiotics and inhibitors.
Phage display has proven to be an effective methodology for the
selection of binding partners of high affinity or altered specificity
(26). Monovalent display of a protein of interest can often
be achieved by fusing the gene encoding the protein to the N terminus
of the M13 gene III coat protein (17). High-affinity variants can then be obtained by creating phage libraries containing mutants of the protein of interest and sequencing the corresponding DNA
packaged in the phagemid particles after several rounds of binding
selection (20). Here we describe the cloning of the BLIP
gene into a new phagemid vector. The vector encodes chloramphenicol resistance and contains an amber codon at the 5' end of gene III. BLIP
is fused at its N terminus to the
-lactamase signal sequence and at
its C terminus to the protein encoded by gene III of the phage (g3p).
Transcription of the fusion is controlled by the constitutive
-lactamase promoter (4). Specific binding of phage
containing the BLIP-g3p fusion to immobilized
-lactamase is
demonstrated to occur with nanomolar affinity. This system can now be
used to engineer new BLIP binding specificities.
 |
MATERIALS AND METHODS |
Bacterial strains.
Escherichia coli XL1-Blue
(2) [F'::Tn10
proA+B+ lacIq
(lacZ)M15/recA1 endA1 gyr96(Nalr)
thi hsdR17 (r
m+) supE44
relA1 lac] was used for transformations of ligations, and
E. coli TG1 (10) [F' traD36+
lacIq
(lacZ)M15 proA+
B+/supE
(hsdM mcrB) (r
m
McrB
) thi
(lac
proAB) was used for production, amplification, and determination
of the titer of bacteriophage.
PCR and cloning.
The phagemid encoding the BLIP-g3p fusion
was constructed by inserting a 1,365-bp
XbaI-BamHI fragment containing gene III from
phagemid phGHamg3 (16) into
XbaI-BamHI-digested pBCKS+ (Stratagene) to create
plasmid pG3-CMP. The pG3-CMP plasmid was digested with SalI,
the 5' overhangs were filled-in with Klenow polymerase and
deoxynucleoside triphosphates, and the ends were religated to destroy
the SalI site and create plasmid pG3-C2 (Fig. 1). A construct containing the coding
sequence of TEM-1
-lactamase fused to gene III was then created by
PCR amplification of the blaTEM-1 gene from
plasmid pBG66-N78 (14). This plasmid was constructed
previously and contains a blaTEM-1 gene with a
SalI site inserted at nucleotide position 284 of the
published sequence (29), which is the codon for the third
amino acid position beyond the cleavage site of the
-lactamase
signal sequence (14). Therefore, the SalI site
can be used to fuse other genes behind the promoter and signal sequence
of
-lactamase. The blaTEM-1 gene was
amplified with the following primers: PD-bla1,
5'-CGGGGAGCTCGTTTCTTAGACGTCAGGTGGC-3'; and
PD-bla2, 5'-CCCCGTCTAGACCCAATGCTTAATCAGTGAG-3'.
Enzyme restriction sites are underlined. The primer PD-bla1
contains a SacI site; the primer PD-bla2 contains an
XbaI site. The PCR was performed with the Advantage cDNA PCR
kit from Clontech, Inc., using the buffer conditions recommended by the
manufacturer. The reaction mixtures were cycled 30 times at 94°C for
1 min, followed by 64°C for 4 min. After cycle 30, the reaction
mixtures were incubated at 64°C for 10 min. The PCR product was
digested with SacI and XbaI and inserted into
SacI-XbaI-digested pG3-C2 plasmid to create pG3-C3. The SacI-XbaI fragment of pG3-C3 contains
approximately 150 bp of sequence upstream of the
blaTEM-1 gene and therefore contains the
constitutive
-lactamase promoter. The XbaI site is the
point of fusion between
-lactamase and gene III. There is an amber
codon at the fusion site, and so the fusion protein will only be made
in an amber suppressor strain of E. coli.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 1.
Maps of the plasmids used in this study. Restriction
endonuclease sites used for the construction of the vectors (Materials
and Methods) are also shown.
|
|
S. clavuligerus genomic DNA was used as a template for
amplification of the
bli gene.
S. clavuligerus
(ATCC 27064) cultures
were grown in Trypticase soy agar broth
containing 1% starch for
64 h. Chromosomal DNA was isolated with
the Puregene kit (Gentra)
for gram-positive bacteria. The
bli gene was amplified with the
following primers: BLIPXHOI,
5'-CGGGCCGG
CTCGAGGAGCGGGGGTGATGACCGGGGCGAAGTTC-3';
and BLIPXBAI,
5'-CGGGCCG
TCTAGAATACAAGGTCCCACTGCCGCTTG-3'.
Enzyme
restriction sites are underlined. The primer BLIPXHOI
contains
an
XhoI site; the primer BLIPXBAI contains an
XbaI site. The primers
were designed to amplify only the
mature portion of BLIP, which
includes codons 37 to 201 of the
bli gene (
8). The PCR conditions
were identical
to those described above for the
blaTEM-1 gene.
The BLIP PCR product was purified with a QIAquick PCR purification
kit
from Qiagen according to the instructions of the manufacturer.
The
purified product was digested with
XhoI and
XbaI
and gel purified
on a SeaPlaque low-melting-point agarose gel with the
protocol
of reference
22. The pG3-C3 plasmid was
digested with
SalI and
XbaI to release the

-lactamase gene. The remainder of the vector
was purified from the
released

-lactamase gene by low-melting-point
agarose. The
XhoI-
XbaI-digested BLIP fragment was then ligated
into the
SalI-
XbaI-digested pG3-C3 vector to
create a fusion of
BLIP at its N terminus to the

-lactamase signal
sequence and
at its C terminus to g3p. The ligation was electroporated
into
E. coli XL1-Blue (
2), and individual
colonies were screened
for BLIP inserts by DNA restriction enzyme
analysis.
Phage preparation and panning.
After overnight growth,
E. coli cells were removed by centrifugation, and the phage
were precipitated from the supernatant with a 1/5 volume of 20%
polyethylene glycol-2.5 M NaCl. The phage were pelleted by
centrifugation and resuspended in 1/100 of the original culture volume
of STE (0.1 M NaCl, 10 mM Tris-Cl [pH 8.0], 1 mM EDTA [pH 8.0]).
The phage titer was determined by making serial dilutions of a 0.1-ml
total volume and adding 0.2 ml of E. coli TG1 cells.
Aliquots of 0.15 ml were plated on Luria-Bertani agar supplemented with
12.5 µg of chloramphenicol per ml. After overnight growth at 37°C,
the number of colonies was determined and the titer was calculated.

-Lactamase was immobilized for panning by covalent attachment to
1-µm-diameter oxirane-acrylic beads (Sigma) by using a modified
version of the method of Lowman and Wells (
17). Fifty
milligrams
of beads was suspended in 0.1 M sodium carbonate buffer (pH
8.6)
and was incubated with purified TEM-1

-lactamase at a
concentration
of 0.04 mg/ml for 24 h at 4°C. Unreacted oxirane
groups were blocked
by incubation with 10 mg of bovine serum albumin
(BSA) per ml
overnight at 4°C. The beads were then pelleted and
washed several
times with buffer A which is Tris-buffered-saline
(
25) containing
1 mg of BSA per ml and 0.5 g of Tween
20 per liter. The beads
were stored in buffer A in a final volume of
0.5 ml. For panning,
10
11 phage were added to 5 mg of

-lactamase-conjugated oxirane beads
in a final volume of 0.5 ml in
buffer A. The binding mixture was
incubated for 2 h at room
temperature with rocking to reach equilibrium.
The beads were then
washed 10 times with 0.75 ml of buffer A.
The bound phage were eluted
from the beads by incubation with
0.2 ml of elution buffer (0.1 M
glycine [pH 2.2], 1 mg of BSA
per ml, 0.5 g of Tween 20 per
liter, 0.1 M KCl) for 30 min. The
elution mixture was neutralized with
25 µl of 1 M Tris-Cl (pH
8.0). The phage titer of the elution mixture
was determined as
described above. The eluted phage were amplified by
adding 0.15
ml of the neutralized elution mixture to 5 ml of
E. coli TG1 cells.
After 30 min of incubation at room temperature, 25 ml of 2YT medium
(
25) was added along with 10
9
VCS M13 helper phage (Stratagene). The phage were precipitated
as
described above after overnight incubation with shaking at
37°C.
Phage ELISA.
A two-step phage enzyme-linked immunosorbent
assay (ELISA) (6) was performed to measure BLIP phage
affinity for TEM-1
-lactamase. Microtiter plates (Nunc; Maxisorp, 96 wells each) were coated with purified TEM-1
-lactamase (at 10 µg/ml) in 50 mM sodium carbonate (pH 9.6) at 4°C overnight. The
plates were then blocked with SuperBlock (Pierce) for 2 h at room
temperature. Serial dilutions of the BLIP phage stock were added to the
wells and incubated for 2 h at room temperature in buffer A at a
final volume of 0.15 ml. The plates were then washed several times with
buffer A, and the bound phage were probed with a sheep anti-M13
polyclonal antibody conjugated to horseradish peroxidase (HRP). To
determine phage affinity, serial dilutions of
-lactamase and a
subsaturating concentration of 1.3 × 1011 BLIP phage
were added to wells in 0.1 ml of buffer A. After 2 h at room
temperature, the wells were washed multiple times with buffer A, and
bound phage were probed as described above. Affinities (IC50) were calculated as the concentration of competing
-lactamase that resulted in half-maximal BLIP phage binding. The
half-maximal concentration was calculated by converting the data in
Fig. 3 from log to linear values and fitting the binding curve to the equation for a hyperbola.
 |
RESULTS |
Construction of a BLIP phage display vector.
A new phagemid
vector, pG3-C3, was constructed for the display of BLIP (Fig. 1). The
pG3-C3 phagemid encodes chloramphenicol resistance and is designed to
express heterologous proteins as fusions at their N terminus to the
signal sequence of TEM-1
-lactamase. In addition, the heterologous
proteins are fused at their C terminus to the g3p of M13 for display on
the surface of the bacteriophage. The fusion protein is expressed under
the control of the constitutive
-lactamase promoter. Because there
is an amber codon at the fusion junction between the heterologous
protein and g3p, it is necessary to express the fusion in an amber
suppressor-containing strain of E. coli. The pG3-C3 plasmid
was constructed by insertion of a SacI-XbaI DNA
fragment containing the promoter and gene encoding TEM-1
-lactamase
into the pG3-C3 plasmid, as shown in Fig. 1. The
blaTEM-1 gene that was inserted was previously
engineered to contain a SalI linker insertion at the codon
for the third amino acid position beyond the cleavage site of the
-lactamase signal sequence (14). The SalI
linker provides a site to fuse a heterologous gene encoding a protein
that will be secreted under the control of the
-lactamase signal
sequence. pG3-BLIP was constructed by PCR amplification of the
bli gene by using primers containing XhoI and
XbaI sites. The bli fragment was then inserted
into the SalI-XbaI-digested pG3-C3 vector (Fig.
1). The resulting phagemid is designed to express the BLIP-g3p fusion,
which, after cleavage of the
-lactamase signal sequence, contains
the entire amino acid sequence of the mature form of BLIP with an
additional seven N-terminal amino acids (Fig.
2). DNA sequence analysis of the entire
BLIP-encoding fragment as well as the fusion junctions with the
-lactamase signal and gene III was performed with clones that were
shown to contain the BLIP insertion by DNA restriction enzyme analysis.
All four of the clones sequenced were found to contain missense or
frameshift mutations and therefore were not suitable for further
testing.

View larger version (6K):
[in this window]
[in a new window]
|
FIG. 2.
Amino acid sequence of junctions between the
-lactamase signal sequence (bla signal) and the N terminus of BLIP
and the C terminus of BLIP and the N terminus of g3p. The site of the
cleavage site for signal peptidase is shown. The glutamate residue
three positions downstream from the signal cleavage site is the last
amino acid encoded by the blaTEM-1 gene. It is
followed by four-amino-acid segment encoded by the SalI
linker DNA that was inserted in the blaTEM-1
gene. The alanine marked as "start BLIP" is the first amino acid in
the construct encoded by the bli gene. The amber codon at
the junction of BLIP-g3p is shown as a glutamine, which is incorporated
in the amber suppressor strain used in this study. The BLIP protein is
fused to amino acid position 267 of g3p.
|
|
In an effort to identify a clone with the wild-type BLIP sequence,
approximately 10,000 colonies were pooled after transformation
of the
ligation mix of the BLIP PCR fragment with the pG3-C3 vector.
Helper
phage were added to the pooled colony culture, and phage
were isolated.
The phage were bound to oxirane beads conjugated
to

-lactamase,
washed extensively, and then eluted with a low-pH
buffer as described
in Materials and Methods. The phage isolated
in this manner were
predicted to contain a functional BLIP fusion
protein. DNA sequence
analysis of four clones from the elution
identified one clone with the
wild-type sequence and three clones
with a D163N substitution near the
C terminus of BLIP. The clone
with the wild-type sequence was
characterized
further.
Phage ELISA to demonstrate
-lactamase-specific binding.
A
two-step phage ELISA method was used to demonstrate that BLIP is
functionally displayed on the surface of the bacteriophage and that the
phage bind specifically to
-lactamase. For this purpose, ELISA
plates were coated with purified TEM-1
-lactamase, and serial
dilutions of phage displaying wild-type BLIP were allowed to bind to
the immobilized protein in the presence of a large excess of BSA. After
washing, bound phage were stained with HRP-conjugated anti-M13
antibody. The binding curve in Fig. 3A
demonstrates that the pG3-BLIP phage bind
-lactamase. To quantitate
binding, ELISA plates were coated with
-lactamase and a constant
subsaturating concentration of pG3-BLIP phage was added with serial
dilutions of purified
-lactamase. As seen in Fig. 3B, the pG3-BLIP
phage were competed off of the immobilized
-lactamase with soluble
-lactamase at an IC50 of 1 nM. This affinity compares
favorably to the published Ki value of 0.6 nM
for the BLIP-
-lactamase interaction (28). These results
show that BLIP is expressed on the surface of the bacteriophage in a
form that binds tightly and specifically to
-lactamase.

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 3.
Two-step phage ELISA results. (A) Binding curve to
determine the subsaturation concentration of phage to use in step 2. A
total of 1.3 × 1011 phage were used in step 2. (B)
Plot showing ELISA measurements of pG3-BLIP phage binding to
immobilized -lactamase. The IC50 given shows the
concentration of competing -lactamase that results in half-maximal
binding to the phagemid.
|
|
Specific enrichment of BLIP phage by panning on
-lactamase.
In order to use the pG3-BLIP phagemid to engineer BLIP for altered
binding properties, it is necessary to be able to select binding phage
by panning on an immobilized substrate. This was tested by attaching
purified
-lactamase to oxirane-acrylic beads and incubating the
beads with 1011 phage from the pG3-BLIP phage stock in the
presence of a large excess of BSA. Two control experiments were
performed to demonstrate that phage binding to the beads was dependent
on the BLIP-
-lactamase interaction. First, an internal control
experiment was performed by adding 1011 phage that did not
display BLIP along with 1011 pG3-BLIP phage to the oxirane
beads conjugated to
-lactamase. The phagemid pG3-SPT, which produced
the nondisplaying phage, was constructed by inserting a gene cassette
encoding spectinomycin resistance (23) into the
chloramphenicol resistance gene of pG3-C2 (Fig. 1). The advantage of
this system is that the extent of enrichment of nondisplaying phage
versus BLIP-displaying phage can be determined simply by determining
the titer of the phage recovered from the oxirane beads on
spectinomycin-containing agar plates as well as
chloramphenicol-containing agar plates. The results in Table
1 illustrate that 27-fold more pG3-BLIP
phage were recovered from the
-lactamase beads than nondisplaying
phage when no soluble
-lactamase was added to complete for binding to the pG3-BLIP phage (compare pG3-BLIP versus pG3-SPT in the column
with 0 µM
-lactamase added). As increasing amounts of soluble
-lactamase were added, the enrichment of pG3-BLIP phage over
nondisplaying phage decreased to threefold when 10 µM soluble
-lactamase was added. Therefore, soluble
-lactamase is able to
compete off the binding of pG3-BLIP phage to the
-lactamase-coated oxirane beads. These data show that BLIP phage can be specifically enriched by a round of panning against immobilized
-lactamase.
For the second control, 10
11 pG3-BLIP phage along with
10
11 nondisplaying pG3-SPT phage were incubated with
oxirane beads to which
only BSA had been attached. The data in Table
1
indicate that
13-fold more BLIP phage were bound to

-lactamase than
to the
BSA control (compare pG3-BLIP in the column with 0 µM

-lactamase
added versus that with BSA beads). In addition, there was
only
a twofold difference in the number of BLIP phage versus
nondisplaying
phage recovered from the BSA beads (compare pG3-BLIP and
pG3-SPT
in the BSA bead column). This is in contrast to the 27-fold
difference
between pG3-BLIP phage and nondisplaying phage recovered
from

-lactamase beads described above. These data provide further
evidence that BLIP phage bind specifically to immobilized

-lactamase.
 |
DISCUSSION |
Phage display is a powerful method for engineering the binding
affinity and specificity of many different molecules, including antibody fragments, enzymes, hormones, protease inhibitors, and DNA
binding proteins (reviewed in references 5 and
20). The ability to use phage display to alter the
binding properties of a protein depends on whether a polypeptide can be
expressed and displayed on the surface of the bacteriophage in a
folded, functional form. Here we have displayed BLIP as a fusion to g3p
and have shown that bacteriophage containing the fusion bind
specifically and with high affinity to
-lactamase.
Display of functional BLIP was accomplished by constructing a new phage
display vector that allowed BLIP to be expressed under the control of
the constitutive TEM-1
-lactamase promoter and secreted under the
direction of the
-lactamase signal sequence. Many phage display
vectors use the lac promoter for expression of the
heterologous protein-g3p fusion (1, 13). Exposure of
E. coli to IPTG can induce the lac promoter to
high levels of transcription. However, in the absence of IPTG, there is
still significant transcription because the bacterial cell usually does not contain enough lac repressor to bind all of the
lac promoters from a multicopy plasmid (9). For
phage production, IPTG is not used because of toxicity of the g3p
fusion proteins and the resultant low phage titer (13). The
-lactamase promoter is weak and is not inducible (4). The
low levels of transcription of the BLIP-g3p fusion are not toxic to
E. coli, and titers of 1012 to 1013
phage/ml were routinely obtained in the experiments reported here.
Because of the high frequency of frameshift mutations in the BLIP gene
found among transformants after insertion of the BLIP gene into the
pG3-C3 vector, it was necessary to obtain a nonmutant sequence by
functional selection for BLIP phage that bound to immobilized
-lactamase. It is unclear why such a high frequency of clones
contained frameshift mutations in BLIP in the nonselected population.
Presumably it is due to a high frequency of polymerase errors during
PCR. A possible reason for this is the very high G-C content of the
BLIP gene. The fragment of BLIP cloned into the pG3-C3 vector is 69%
G-C. G-C DNA templates are often difficult to amplify by PCR
(11). The difficulty may be due to the higher melting
temperature of G-C-rich template DNA or to extensive secondary structure in the template (24). The finding of a high
frequency of frameshift mutations in the amplified BLIP DNA may
indicate that PCR of G-C-rich DNA has reduced fidelity.
The development of the BLIP phage system will now be exploited to
determine which residues on BLIP are critical for TEM-1
-lactamase
binding and to select for variants that bind tightly to other
-lactamases or penicillin-binding proteins. To achieve this,
libraries of random mutants of BLIP will be created in the pG3-BLIP
vector. The phage libraries will then be panned on purified TEM-1
-lactamases and other
-lactamases as described here.
 |
ACKNOWLEDGMENTS |
We thank Gary Rudgers for comments on the manuscript.
This work was supported in part by NIH grant AI32956.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology and Immunology, Baylor College of Medicine, Houston, TX 77030. Phone: (713) 798-5609. Fax: (713) 798-7375. E-mail:
timothyp{at}bcm.tmc.edu.
 |
REFERENCES |
| 1.
|
Barbas, C. F., III, and R. A. Lerner.
1991.
Combinatorial immunoglobulin libraries on the surface of phage: rapid selection of antigen-specific Fabs.
Methods Companion Methods Enzymol.
2:119-124.
|
| 2.
|
Bullock, W. O.,
J. M. Fernandez, and J. M. Short.
1987.
XL1-Blue: a high efficiency plasmid transforming recA Escherichia coli strain with beta-galactosidase selection.
BioTechniques
5:376-379.
|
| 3.
|
Bush, K.,
G. A. Jacoby, and A. A. Medeiros.
1995.
A functional classification scheme for -lactamases and its correlation with molecular structure.
Antimicrob. Agents Chemother.
39:1211-1233[Medline].
|
| 4.
|
Chen, S.-T., and R. C. Clowes.
1984.
Two improved promoter sequences for the -lactamase expression arising from a single base-pair substitution.
Nucleic Acids Res.
12:3219-3234[Abstract/Free Full Text].
|
| 5.
|
Clackson, T., and J. Wells.
1994.
In vitro selection from protein and peptide libraries.
Trends Biotechnol.
12:173-184[Medline].
|
| 6.
|
Cunningham, B. C.,
D. G. Lowe,
B. Li,
B. D. Bennet, and J. A. Wells.
1994.
Production of an atrial natriuretic peptide variant that is specific for type A receptor.
EMBO J.
13:2508-2525[Medline].
|
| 7.
|
Davies, J.
1994.
Inactivation of antibiotics and the dissemination of resistance genes.
Science
264:375-382[Abstract/Free Full Text].
|
| 8.
|
Doran, J. L.,
B. K. Leskiw,
S. Aippersbach, and S. E. Jensen.
1990.
Isolation and characterization of a -lactamase-inhibitory protein from Streptomyces clavuligerus and cloning and analysis of the corresponding gene.
J. Bacteriol.
172:4909-4918[Abstract/Free Full Text].
|
| 9.
|
Dubendorff, J. W., and F. W. Studier.
1991.
Controlling basal expression in an inducible T7 expression system by blocking the target T7 promoter with lac repressor.
J. Mol. Biol.
219:45-59[Medline].
|
| 10.
|
Gibson, T. J.
1984.
Ph.D. thesis.
Cambridge University, Cambridge, United Kingdom.
|
| 11.
|
Henke, W.,
K. Herdel,
K. Jung,
D. Schnorr, and S. A. Loening.
1997.
Betaine improves the PCR amplification of GC-rich DNA sequences.
Nucleic Acids Res.
25:3957-3958[Abstract/Free Full Text].
|
| 12.
|
Henquell, C.,
C. Chanal,
D. Sirot,
R. Labia, and J. Sirot.
1995.
Molecular characterization of nine different types of mutants among 107 inhibitor-resistant TEM -lactamases from clinical isolates of Escherichia coli.
Antimicrob. Agents Chemother.
39:427-430[Abstract/Free Full Text].
|
| 13.
|
Hoogenboom, H. R.,
A. D. Griffiths,
K. S. Johnson,
D. J. Chiswell,
P. Hudson, and G. Winter.
1991.
Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains.
Nucleic Acids Res.
19:4133-4137[Abstract/Free Full Text].
|
| 14.
|
Huang, W.,
J. Petrosino,
M. Hirsch,
P. S. Shenkin, and T. Palzkill.
1996.
Amino acid sequence determinants of -lactamase structure and activity.
J. Mol. Biol.
258:688-703[Medline].
|
| 15.
|
Imtiaz, U.,
E. Billings,
J. R. Knox,
E. K. Manavathu,
S. A. Lerner, and S. Mobashery.
1993.
Inactivation of class A -lactamases by clavulanic acid: the role of arginine 244 in a proposed nonconcerted sequence of events.
J. Am. Chem. Soc.
115:4435-4442.
|
| 16.
|
Lowman, H. B.,
S. H. Bass,
N. Simpson, and J. A. Wells.
1991.
Selecting high-affinity binding proteins by monovalent phage display.
Biochemistry
30:10832-10838[Medline].
|
| 17.
|
Lowman, H. B., and J. A. Wells.
1991.
Monovalent phage display: a method for selecting variant proteins from random libraries.
Methods Companion Methods Enzymol.
3:205-216.
|
| 18.
|
Neu, H. C.
1992.
The crisis in antibiotic resistance.
Science
257:1064-1073.
|
| 19.
|
Neu, H. C., and K. P. Fu.
1978.
Clavulanic acid, a novel inhibitor of -lactamases.
Antimicrob. Agents Chemother.
14:650-655[Abstract/Free Full Text].
|
| 20.
|
O'Neil, K. T., and R. H. Hoess.
1995.
Phage display: protein engineering and directed evolution.
Curr. Opin. Struct. Biol.
5:443-449[Medline].
|
| 21.
|
Parker, R. H., and M. Eggleston.
1987.
-Lactamase inhibitors: another approach to overcoming antimicrobial resistance.
Infect. Control
8:36-40[Medline].
|
| 22.
|
Qian, L., and M. Wilkinson.
1991.
DNA fragment purification: removal of agarose 10 minutes after electrophoresis.
BioTechniques
10:736[Medline].
|
| 23.
|
Reece, K. S., and G. J. Phillips.
1995.
New plasmids carrying antibiotic-resistance cassettes.
Gene
165:141-142[Medline].
|
| 24.
|
Rees, W. A.,
T. D. Yager,
J. Korte, and P. H. von Hippel.
1993.
Betaine can eliminate the base pair composition dependence of DNA melting.
Biochemistry
32:137-144[Medline].
|
| 25.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 26.
|
Smith, G. P.
1985.
Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface.
Science
228:1315-1317[Abstract/Free Full Text].
|
| 27.
|
Strynadka, N. C. J.,
S. E. Jensen,
P. M. Alzari, and M. N. G. James.
1996.
A potent new mode of -lactamase inhibition revealed by the 1.7Å X-ray crystallographic structure of the TEM-1-BLIP complex.
Nature Struct. Biol.
3:290-297[Medline].
|
| 28.
|
Strynadka, N. C. J.,
S. E. Jensen,
K. Johns,
H. Blanchard,
M. Page,
A. Matagne,
J.-M. Frere, and M. N. G. James.
1994.
Structural and kinetic characterization of a -lactamase-inhibitor protein.
Nature
368:657-660[Medline].
|
| 29.
|
Sutcliffe, J. G.
1978.
Nucleotide sequence of the ampicillin resistance gene of Escherichia coli plasmid pBr322.
Proc. Natl. Acad. Sci. USA
75:3737-3741[Abstract/Free Full Text].
|
| 30.
|
Wiedemann, B.,
C. Kliebe, and M. Kresken.
1989.
The epidemiology of -lactamases.
J. Antimicrob. Chemother.
24:1-24[Free Full Text].
|
Antimicrobial Agents and Chemotherapy, November 1998, p. 2893-2897, Vol. 42, No. 11
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Zhang, Z., Palzkill, T.
(2004). Dissecting the Protein-Protein Interface between {beta}-Lactamase Inhibitory Protein and Class A {beta}-Lactamases. J. Biol. Chem.
279: 42860-42866
[Abstract]
[Full Text]
-
Zhang, Z., Palzkill, T.
(2003). Determinants of Binding Affinity and Specificity for the Interaction of TEM-1 and SME-1 {beta}-Lactamase with {beta}-Lactamase Inhibitory Protein. J. Biol. Chem.
278: 45706-45712
[Abstract]
[Full Text]
-
Huang, W., Beharry, Z., Zhang, Z., Palzkill, T.
(2003). A broad-spectrum peptide inhibitor of {beta}-lactamase identified using phage display and peptide arrays. Protein Eng Des Sel
16: 853-860
[Abstract]
[Full Text]
-
Rudgers, G. W., Palzkill, T.
(1999). Identification of Residues in beta -Lactamase Critical for Binding beta -Lactamase Inhibitory Protein. J. Biol. Chem.
274: 6963-6971
[Abstract]
[Full Text]
-
Petrosino, J., Rudgers, G., Gilbert, H., Palzkill, T.
(1999). Contributions of Aspartate 49 and Phenylalanine 142 Residues of a Tight Binding Inhibitory Protein of beta -Lactamases. J. Biol. Chem.
274: 2394-2400
[Abstract]
[Full Text]
-
Huang, W., Zhang, Z., Palzkill, T.
(2000). Design of Potent beta -Lactamase Inhibitors by Phage Display of beta -Lactamase Inhibitory Protein. J. Biol. Chem.
275: 14964-14968
[Abstract]
[Full Text]